KR102755284B1 - 골 표적화 항체 - Google Patents

골 표적화 항체 Download PDF

Info

Publication number
KR102755284B1
KR102755284B1 KR1020237042558A KR20237042558A KR102755284B1 KR 102755284 B1 KR102755284 B1 KR 102755284B1 KR 1020237042558 A KR1020237042558 A KR 1020237042558A KR 20237042558 A KR20237042558 A KR 20237042558A KR 102755284 B1 KR102755284 B1 KR 102755284B1
Authority
KR
South Korea
Prior art keywords
ser
val
thr
leu
mab1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237042558A
Other languages
English (en)
Korean (ko)
Other versions
KR20230172039A (ko
Inventor
화웨이 추
성해 박
제임스 스테파노
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Priority to KR1020257000987A priority Critical patent/KR20250012197A/ko
Publication of KR20230172039A publication Critical patent/KR20230172039A/ko
Application granted granted Critical
Publication of KR102755284B1 publication Critical patent/KR102755284B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237042558A 2017-01-20 2018-01-19 골 표적화 항체 Active KR102755284B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257000987A KR20250012197A (ko) 2017-01-20 2018-01-19 골 표적화 항체

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
US62/448,763 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies
KR1020197024021A KR102613463B1 (ko) 2017-01-20 2018-01-19 골 표적화 항체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024021A Division KR102613463B1 (ko) 2017-01-20 2018-01-19 골 표적화 항체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000987A Division KR20250012197A (ko) 2017-01-20 2018-01-19 골 표적화 항체

Publications (2)

Publication Number Publication Date
KR20230172039A KR20230172039A (ko) 2023-12-21
KR102755284B1 true KR102755284B1 (ko) 2025-01-22

Family

ID=61581744

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237042558A Active KR102755284B1 (ko) 2017-01-20 2018-01-19 골 표적화 항체
KR1020197024021A Active KR102613463B1 (ko) 2017-01-20 2018-01-19 골 표적화 항체
KR1020257000987A Pending KR20250012197A (ko) 2017-01-20 2018-01-19 골 표적화 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197024021A Active KR102613463B1 (ko) 2017-01-20 2018-01-19 골 표적화 항체
KR1020257000987A Pending KR20250012197A (ko) 2017-01-20 2018-01-19 골 표적화 항체

Country Status (17)

Country Link
US (3) US10844115B2 (enExample)
EP (1) EP3571226A2 (enExample)
JP (3) JP7227138B2 (enExample)
KR (3) KR102755284B1 (enExample)
CN (2) CN111032690B (enExample)
AR (1) AR110755A1 (enExample)
AU (1) AU2018210270A1 (enExample)
BR (1) BR112019013986A2 (enExample)
CA (1) CA3050884A1 (enExample)
IL (2) IL317592A (enExample)
MX (2) MX2019008549A (enExample)
MY (2) MY194819A (enExample)
SG (1) SG11201906663VA (enExample)
TW (3) TW202421659A (enExample)
UY (1) UY37576A (enExample)
WO (1) WO2018136698A2 (enExample)
ZA (1) ZA201907673B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN112703038B (zh) * 2018-07-10 2025-07-29 赛诺菲 靶向CD38和TGF-β的抗癌组合疗法
WO2020104390A2 (en) * 2018-11-19 2020-05-28 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
IL308175A (en) 2021-05-07 2023-12-01 Baylor College Medicine Treatment of moderate to severe defective bone formation
JP2024526920A (ja) * 2021-07-20 2024-07-19 ウィリアム マーシュ ライス ユニバーシティ 骨標的療法のための操作された組成物
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
BR0317896A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
JP2009521496A (ja) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
MX2011006501A (es) 2008-12-22 2011-07-12 Novo Nordisk As Anticuerpos contra inhibidor de la via de factor de tejido.
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
MY171135A (en) 2011-06-03 2019-09-27 Xoma Technology Ltd Antibodies specific for tgf-beta
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
DK2855527T3 (en) 2012-05-31 2018-11-26 Innate Pharma TLR3 BINDERS
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013331154B2 (en) 2012-10-17 2018-02-01 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US9598486B2 (en) * 2013-03-20 2017-03-21 Genzyme Corporation Methods for treating osteogenesis imperfecta
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3119419B1 (en) * 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
WO2016057933A1 (en) 2014-10-10 2016-04-14 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
EP3277716B1 (en) 2015-04-03 2020-06-24 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途

Also Published As

Publication number Publication date
IL268114B1 (en) 2025-01-01
JP2023058590A (ja) 2023-04-25
KR102613463B1 (ko) 2023-12-15
US20210163584A1 (en) 2021-06-03
BR112019013986A2 (pt) 2020-03-03
CN118121696A (zh) 2024-06-04
KR20190105236A (ko) 2019-09-16
ZA201907673B (en) 2021-05-26
MX2019008549A (es) 2019-09-11
US10844115B2 (en) 2020-11-24
WO2018136698A2 (en) 2018-07-26
IL268114B2 (en) 2025-05-01
US12098194B2 (en) 2024-09-24
TWI832600B (zh) 2024-02-11
SG11201906663VA (en) 2019-08-27
US20250074975A1 (en) 2025-03-06
KR20250012197A (ko) 2025-01-23
JP7597836B2 (ja) 2024-12-10
TW202330597A (zh) 2023-08-01
CN111032690A (zh) 2020-04-17
TW201839013A (zh) 2018-11-01
KR20230172039A (ko) 2023-12-21
IL268114A (en) 2019-09-26
MY207919A (en) 2025-03-27
MY194819A (en) 2022-12-17
IL317592A (en) 2025-02-01
TWI788321B (zh) 2023-01-01
RU2019126026A (ru) 2021-02-20
AU2018210270A1 (en) 2019-09-05
US20180208650A1 (en) 2018-07-26
RU2019126026A3 (enExample) 2021-11-09
MX2022008073A (es) 2022-07-27
JP7227138B2 (ja) 2023-02-21
UY37576A (es) 2018-10-31
AR110755A1 (es) 2019-05-02
CA3050884A1 (en) 2018-07-26
TW202421659A (zh) 2024-06-01
JP2025028981A (ja) 2025-03-05
WO2018136698A3 (en) 2018-08-30
CN111032690B (zh) 2024-03-26
JP2020505919A (ja) 2020-02-27
EP3571226A2 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
KR102755284B1 (ko) 골 표적화 항체
KR20220110224A (ko) Bcma에 결합하는 항체 및 이의 용도
KR20210075129A (ko) 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
JP2018526974A (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
CN108659112B (zh) 一种非对称双特异性抗体
AU2020316495A1 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
KR20220071177A (ko) 인간화 항-vegf 단클론 항체
CN116925222A (zh) 抗pvrig抗体、其药物组合物及用途
CN108601833A (zh) 甲状旁腺激素-抗rankl抗体融合化合物
CN104558194A (zh) 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
RU2801206C2 (ru) Антитела, нацеливающиеся на костную ткань
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
HK1147107B (en) Improved antibody molecules
HK1147107A1 (en) Improved antibody molecules

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231208

Application number text: 1020197024021

Filing date: 20190816

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240205

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241008

PG1601 Publication of registration